• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Lubrizol Completes Acquisition of Laboratoire Phenobio

Share:

March 25, 2019

The Lubrizol Corporation announces the acquisition of Laboratoire Phenobio, an innovative supplier of naturally-derived extracts and botanical active ingredients. Recognized across the world as a pioneer in botanical extracts and natural performance ingredients, this addition expands Lubrizol’s existing capabilities to provide clean natural ingredients across the cosmetic, nutraceutical and life sciences industries.

Located near the Bordeaux region in France, the company’s unique capabilities in subcritical water extraction (SWE) of botanical biomass, coupled with their energy-economic and eco-responsible technologies provide significant value to Lubrizol’s global sustainability efforts. This expertise includes a technology used to extract phytoactives from botanical raw materials and is also commonly known as pressurized low polarity water (PLPW). The technology involves extraction of a broad range of phytoactives that are not normally obtained with only water.

“Lubrizol continues to invest in innovative technologies to offer step change formulations for the personal care and life sciences markets” states Deb Langer, Lubrizol vice president and general manager of personal, home and healthcare. “With this acquisition, Lubrizol customers will have access to novel botanical extracts compliant with ECOCERT® and COSMOS standards that meet the naturality and sustainability expectations end users are requiring on a global basis. Additionally, our preferred partners will have access to final formulations using this exciting new technology.”

Date: March 25, 2019

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Source: GlobeNewswire

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals.Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals.
  • Korean Government, Private Hospital Researchers Develop Medical Imaging Technology Using Machine LearningKorean Government, Private Hospital Researchers Develop Medical Imaging Technology Using Machine Learning
  • Carepayment Reports Record Growth in 2019, Acquires Horizon Health FundCarepayment Reports Record Growth in 2019, Acquires Horizon Health Fund
  • Velocity Clinical Research Begins European Expansion with German Site AcquisitionVelocity Clinical Research Begins European Expansion with German Site Acquisition
  • How COVID-19 Made Employee Safety Work for EmployeesHow COVID-19 Made Employee Safety Work for Employees
  • Bioventus Amends Cartiheal Acquisition StructureBioventus Amends Cartiheal Acquisition Structure
  • Activist investor Starboard Value says it will oppose Bristol-Myers’ $74 billion deal for CelgeneActivist investor Starboard Value says it will oppose Bristol-Myers’ $74 billion deal for Celgene
  • Alliqua BioMedical Inc. and Adynxx, Inc. Announce Merger Agreement to Create NASDAQ-listed Clinical-Stage Pharmaceutical Company with a Focus on Pain and InflammationAlliqua BioMedical Inc. and Adynxx, Inc. Announce Merger Agreement to Create NASDAQ-listed Clinical-Stage Pharmaceutical Company with a Focus on Pain and Inflammation

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications